Lormalzi (donanemab) launched in India for early Alzheimer’s disease targeting amyloid plaques The drug is priced at Rs 91,688 per 350 mg vial and requires intravenous monthly infusion Approved for patients with mild cognitive impairment or mild dementia with confirmed amyloid pathology